Belviq Lawsuit
- Last Updated: November 14th, 2024
Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.
Legally Reviewed
This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.
Fact-Checked
TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.
Belviq Lawsuit Overview
A Belviq Lawsuit may apply to you or your loved one if the diet drug Belviq or Belviq XR was taken prior to a cancer diagnosis.
An experienced Belviq lawyer will be able to assist in protecting your legal rights.
The Food and Drug Administration announced that the popular weight-loss drug Belviq (lorcaserin) would be pulled from the United States market as of February 2020.
Researchers found increased reported cancer rates in people who took Belviq. FDA officials recommend that Belviq users immediately stop taking the medication.
Table of Contents
Lawsuit Updates
-
November 2024 Updates:
No significant updates in the Belviq (lorcaserin) litigation have been announced. While legal proceedings and settlement negotiations remain ongoing, no major settlements or trial dates have been made public.
-
October 2024 Updates:
There have been no developments or news published in the Belviq litigation. No trial dates have been set, and no significant updates have been released. We will continue to monitor the situation closely and provide updates as they become available.
-
September 2024 Updates:
September 1, 2024
Currently, no new updates are available regarding the progress of the litigation. However, the legal battle surrounding the weight-loss drug Belviq (lorcaserin) continues, with plaintiffs alleging that the manufacturer failed to sufficiently warn consumers about the drug’s cancer risks.
-
August 2024 Updates:
August 1, 2024
The litigation over the weight-loss drug Belviq (lorcaserin) is ongoing. Plaintiffs allege that the manufacturer did not adequately warn consumers about the drug’s cancer risks, which led to its recall.
-
February 2024 Updates:
February 1st, 2024:
As of February, no significant judgments or large-scale settlements have been reached in the ongoing Belviq litigation.
Discussions for a potential global resolution between Eisai and plaintiffs continue, albeit without any notable developments to report. Despite ongoing settlement talks, new Belviq-related cases continue to emerge, underscoring the ongoing legal challenges faced by the drug manufacturer.
-
January 2024 Updates:
January 1st, 2023:
As of now, there haven’t been any notable judgments or sizable settlements in the Belviq litigation. Settlement talks persist between Eisai and plaintiffs for a potential global resolution.
Although there are advancements in discussions for settlements, legal representatives remain open to new Belviq-related cases, as individuals continue to file claims against the drug manufacturer
-
November 2023 Updates:
November 1st, 2023:
There have been no significant verdicts or substantial settlements in relation to the Belviq litigation to date.
While progress is being made in settlement talks, legal representatives remain receptive to new Belviq-related cases, as individuals continue to file claims against the drug manufacturer.
-
October 2023 Updates:
October 2nd, 2023:
Negotiations for a worldwide resolution in the Belviq litigation are ongoing, aiming to reach a resolution within this year.
Despite advancements in settlement negotiations, attorneys are still open to accepting new Belviq-related cases, as individuals continue to bring forth claims against the drug manufacturer.
-
September 2023 Updates:
September 6th, 2023:
Plaintiffs’ lawyers are optimistic about the possibility of Eisai reaching a global settlement later this year. Some cases involving Eisai and Arena Pharmaceuticals have already been settled through agreements before going to trial.
Ongoing discussions are taking place regarding potential global settlements.
-
August 2023 Updates:
August 1st, 2023
Efforts to reach a global settlement in the Belviq litigation are still underway, with hopes of resolving the cases sometime this year.
The litigation has been put on hold since 2022 to allow for settlement negotiations, and as of now, no trial dates have been set.
While progress is being made in the settlement talks, lawyers are still accepting new cases related to Belviq, as individuals continue to come forward with claims against the drug manufacturer.
The ongoing negotiations aim to bring closure and resolution to the numerous lawsuits surrounding the weight-loss medication.
-
July 2023 Updates:
There are no new updates regarding the class action lawsuit against Belviq & Belviq XR as of July 1st.
However, Plaintiffs continue to come forward alleging the weight-loss medication caused serious conditions such as cancer, cardiovascular problems, and other adverse effects.
Additionally, settlements are anticipated in the near future as the cases remain ongoing.
Our team is closely monitoring the situation and will provide any further information as it becomes available.
-
June 2023 Updates:
Negotiations and settlements are currently underway in the Belviq lawsuit.
However, no finalized agreements are to report at this time.
Further updates will be provided as soon as there are significant developments or official announcements.
-
May 2023 Updates:
Settlements for the Belviq lawsuit are still expected to come to an end, in the near future, as cases continue.
-
April 2023 Updates:
Eisai is currently in talks to withdraw Belviq from U.S. shelves after the FDA flagged the drug for cancer risks.
This comes as the global settlement for the Belviq lawsuits are expected to be determined soon.
-
March 2023 Updates:
A global settlement for Belviq lawsuits are expected in the future.
There have been joint motions filled in multiple districts.
Plaintiffs are in negotiations with Eisai and Arena Pharmaceuticals for a settlement.
There is no MDL for the Belviq lawsuits, but the global settlement is expected to be similar.
What is Belviq and How Does it Work?
Belviq is a popular prescription weight-loss drug sold and produced by Eisai Inc. Belviq works by altering the brain chemical signals responsible for appetite.
The drug is prescribed in combination with exercise and a healthy diet to help adults who are overweight or obese.
The medication does not treat underlying health conditions.
What’s the difference between Belviq and Belviq XR?
Belviq is a 10 mg prescription tablet that patients take two times a day.
Belviq XR is the extended-release form taken once daily.
Is Belviq Dangerous?
The FDA requested Belviq be pulled from the U.S. market because of the drug’s ties to increased cancer rates.
FDA researchers conducted a study on the drug and found that approximately 7.7 percent of patients that took Belviq were diagnosed with cancer compared to 7.1 percent of placebo recipients.
The FDA also found that the longer a patient was on Belviq, the greater his or her risk was of developing cancer.
TruLaw recommends finding out if you qualify for a Belviq Lawsuit instantly using the Bevliq Case Qualification tool.
A Belviq Lawyer may be able to assist with compensation for injuries and medical bills while protecting your legal rights.
Types of Cancers Tied to Belviq
The FDA reported increased rates of pancreatic, lung, and colorectal cancers in Belviq and Belviq XR users.
Does Belviq Cause Cancer?
In January, the FDA announced that Belviq and Belviq XR cancer risks were strong enough to call for the drugs’ removal from the U.S. market.
The agency said it still cannot definitively conclude that Belviq and Belviq cause cancer.
However, officials said the medications’ risks outweigh the benefits and that people taking Belviq should stop immediately.
Other Belviq Dangers
Belviq and Belviq XR have been tied to numerous other side effects.
These include headaches, fatigue, dizziness, nausea, dry mouth, and constipation.
Patients with diabetes who take Belviq / Belviq XR might also experience coughing, back pain, and hypoglycemia.
The drug can also cause slowed heartbeat and heart valve issues.
The medications were rejected by the European Medicines Agency in 2012 due to safety concerns.
Belviq is classified as a Schedule IV controlled substance by the Drug Enforcement Agency.
This means the drug carries risks of dependence.
People who take higher doses than prescribed can experience hallucinations, euphoria, and slowed thinking.
The medication can also adversely interact with other prescriptions.
Note that Belviq / Belviq XR were only approved for people who are overweight (a body-mass index between 27 and 30) or obese (a body-mass index over 30) and have high cholesterol, high blood pressure, or diabetes.
To find out if a Belviq Lawsuit is right for you visit our Bevlviq Instant Case Report Tool or contact TruLaw at (888) 477-3804 to speak with a Belviq Lawyer.
FDA Belviq Recall
The U.S. Food and Drug Administration requested that Belviq, the popular weight-loss medication, be voluntarily pulled from U.S. markets after clinical safety trials tied the drug to increased cancer rates.
Eisai Inc., the medication’s manufacturer, submitted to requests and pulled the drug from the market.
FDA officials said cancer risks tied to Belviq are significant enough to call for the medication’s removal from markets.
Since the drug’s approval, researchers have been conducting a five-year study analyzing its safety profile.
The researchers discovered approximately 7.7 percent of Belviq users had a cancer diagnosis versus the 7.1 percent who took a placebo.
FDA Belviq Recommendations
Patients
FDA officials said people taking Belviq should stop immediately.
Patients should speak with a health professional to find different weight-loss drugs and weight-management programs.
Patients should dispose of Belviq at a drug take-back site or in their household waste using the following techniques:
- Mix the drug into an uninviting material such as used coffee grounds, cat litter, or dirt. Do not crush the medication.
- Put the mix in a sealed container like a plastic bottle or bag.
- Throw away the container in your household trash.
- Remove personal information from the prescription labels, bottles, or packaging. Recycle or throw away the containers.
The FDA is not requiring special cancer screenings for people who took Belviq.
Patients should still undergo regular recommended cancer screenings.
Patients should contact their healthcare provider with any questions.
Healthcare Professionals
The FDA said healthcare providers should immediately stop dispensing and prescribing Belviq and Belviq XR to patients.
Providers should contact any patients currently taking the medication to inform them of the clinical trial results and ask them to stop taking the drug.
Providers should help patients find alternative medications and weight-loss strategies.
Reporting Belviq Side Effects
To help the FDA track Belviq safety issues, the agency encourages patients and health professionals to report adverse reactions and side effects to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.
Information can be submitted through:
- The MedWatch Online Voluntary Reporting Form
- Contacting the FDA at 855-543-DRUG (3784) and pressing 4, or at druginfo@fda.hhs.gov
- Downloading the form from the FDA Medwatch Safety Reporting Website or calling 1-800-332-1088 to request a reporting form, then submitting the completed form by fax to 1-800-FDA-0178 or on the listed return address.
Filing a Belviq Lawsuit
If you took Belviq or Belviq XR and developed cancer or other adverse side effects, you could be eligible for a Belviq / Belviq XR lawsuit.
If you took Belviq or Belviq XR and were diagnosed with colorectal, pancreatic, or lung cancer, we will work to seek the following damages for you:
- Expenses from your medical treatment
- Pain and suffering, both physical and mental, from cancer, treatments, and your recovery time
- Loss of wages and earning capabilities
- Loss of enjoyment of life due to the disease and damages
Hiring a Belviq Lawyer
Hiring an experienced Belviq lawyer is critical for earning full compensation for the suffering endured by you or your loved one.
TruLaw will work with you to successfully pursue your bad drug lawsuit.
We offer free, zero-obligation case consultations for all potential Belviq lawsuit clients.
Find out if you qualify instantly or Contact TruLaw today to learn about your potential case and legal options.
Experienced Attorney & Legal SaaS CEO
With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three. She spent the first decade of her career working as an international tax attorney at Deloitte.
In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.
In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?
At TruLaw, we fiercely combat corporations that endanger individuals’ well-being. If you’ve suffered injuries and believe these well-funded entities should be held accountable, we’re here for you.
With TruLaw, you gain access to successful and seasoned lawyers who maximize your chances of success. Our lawyers invest in you—they do not receive a dime until your lawsuit reaches a successful resolution!
Do you believe you’re entitled to compensation?
Use our Instant Case Evaluator to find out in as little as 60 seconds!
AFFF Lawsuit claims are being filed against manufacturers of aqueous film-forming foam (AFFF), commonly used in firefighting.
Claims allege that companies such as 3M, DuPont, and Tyco Fire Products failed to adequately warn users about the potential dangers of AFFF exposure — including increased risks of various cancers and diseases.
Suboxone Tooth Decay Lawsuit claims are being filed against Indivior, the manufacturer of Suboxone, a medication used to treat opioid addiction.
Claims allege that Indivior failed to adequately warn users about the potential dangers of severe tooth decay and dental injuries associated with Suboxone’s sublingual film version.
Social Media Harm Lawsuits are being filed against social media companies for allegedly causing mental health issues in children and teens.
Claims allege that companies like Meta, Google, ByteDance, and Snap designed addictive platforms that led to anxiety, depression, and other mental health issues without adequately warning users or parents.
Transvaginal Mesh Lawsuits are being filed against manufacturers of transvaginal mesh products used to treat pelvic organ prolapse (POP) and stress urinary incontinence (SUI).
Claims allege that companies like Ethicon, C.R. Bard, and Boston Scientific failed to adequately warn about potential dangers — including erosion, pain, and infection.
Bair Hugger Warming Blanket Lawsuits involve claims against 3M — alleging their surgical warming blankets caused severe infections and complications (particularly in hip and knee replacement surgeries).
Plaintiffs claim 3M failed to warn about potential risks — despite knowing about increased risk of deep joint infections since 2011.
Baby Formula NEC Lawsuit claims are being filed against manufacturers of cow’s milk-based baby formula products.
Claims allege that companies like Abbott Laboratories (Similac) and Mead Johnson & Company (Enfamil) failed to warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants.
Here, at TruLaw, we’re committed to helping victims get the justice they deserve.
Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.
Would you like our help?